Methadone: From pharmacokinetic profile to clinical pharmacology;Méthadone: De la pharmacocinétique à la pharmacologie clinique

Encephale

Volumn 32, Issue 4 I, 2006, Pages 478-486

  Vazquez, V ^a   Gury, C ^b   Laqueille, X ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE

Author keywords

Clinical pharmacology; Drug monitoring; Methadone; Pharmacokinetics; Pharmacological interactions

Indexed keywords

ABACAVIR; AMITRIPTYLINE; AMPRENAVIR; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CIPROFLOXACIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; EFAVIRENZ; FLUCONAZOLE; FLUOXETINE; FLUVOXAMINE; FUSIDIC ACID; LOPINAVIR; METHADONE; MOCLOBEMIDE; NELFINAVIR; NEVIRAPINE; OPIATE AGONIST; PAROXETINE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANXIETY; COMORBIDITY; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GENETIC VARIABILITY; HUMAN; IRRITABILITY; LIVER METABOLISM; MENSTRUATION DISORDER; MENTAL DISEASE; MIOSIS; MUSCLE CRAMP; NAUSEA; PRESCRIPTION; PSYCHOSOCIAL DISORDER; RESPIRATION DEPRESSION; REVIEW; RHINORRHEA; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STEADY STATE; SUBSTITUTION THERAPY; TACHYCARDIA; UROGENITAL TRACT DISEASE; VOMITING; WITHDRAWAL SYNDROME;

EID: 33748251851     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0013-7006(06)76190-5     Document Type: Article

References (46)

1. ALDERMAN CP, FRITH PA. Fluvoxamine-methadone interaction. Aust N Z J Psychiatry 1999 ; 33 : 99-101.
2. BART PA, RIZZARDI PG, GALLANT S et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001 ; 23 : 553-5.
3. BEAUVERIE P, TABURET AM, DESSALLES MC et al. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. Aids 1998 ; 12 : 2510-11.
4. BEAUVERIE PB J, POISSON N, JACQUOT C. Les opiacés dans la prise en charge des toxicomanes. Agence du médicament. Doss CNHIM 1995 ; XVI, 4 : 7-49.
5. BEGRE S, VON BARDELEBEN U, LADEWIG D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002 ; 22 : 211-5.
6. BORG L, HO A, PETERS JE et al. Availability of reliable serum methadone determination for management of symptomatic patients. J Addict Dis 1995 ; 14 : 83-96.
7. CALVO R, LUKAS JC, RODRIGUEZ M et al. Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. Br J Clin Pharmacol 2002 ; 53 : 212-4.
8. CARLOS MA, DU SOUICH P, CARLOS R et al. Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. J Pharm Sci 2002 ; 91 : 1627-38.
9. CIRCULAIRE DGS/DHOS no 2002/57 du 30 janvier 2002 relative à la prescription de la methadone par les médecins exerçant en établissement de santé, dans le cadre de l'initialisation d'un traitement de substitution pour les toxicomanes dépendants majeurs aux opiacés.
10. COBB MN, DESAI J, BROWN LS et al. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998 ; 63 : 655-62.
11. CODD EE, SHANK RP, SCHUPSKY JJ et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics : structural determinants and role in antinociception. J Pharmacol Exp Ther 1995 ; 274 : 1263-70.
12. DAVIES G, KINGSWOOD C, STREET M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996 ; 31 : 410-22.
13. DE VOS JW, UFKES JG, KAPLAN CD et al. L-Methadone and D, L-methadone in methadone maintenance treatment : a comparison of therapeutic effectiveness and plasma concentrations. Eur Addict Res 1998 ; 4 : 134-41.
14. DOLE VP, NYSWANDER MA. Medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965 ; 193 : 646-50.
15. EAP CB, BUCLIN T, BAUMANN P. Interindividual variability of the clinical pharmacokinetics of methadone : implications for the treatment of opioid dependence. Clin Pharmacokinet 2002 ; 41 : 1153-93.
16. GARRIDO MJ, TROCONIZ IF. Methadone : a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999 ; 42 : 61-6.
17. GORMAN AL, ELLIOTT KJ, INTURRISI CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997 ; 223 : 5-8.
18. GOUREVITCH MN, FRIEDLAND GH. Interactions between methadone and medications used to treat HIV infection : a review. Mt Sinai J Med 2000 ; 67 : 429-36.
19. GRAM LF, GUENTERT TW, GRANGE S et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2 : a panel study. Clin Pharmacol Ther 1995 ; 57 : 670-7.
20. GURY C, CANCEIL O, IARIA P. Antipsychotic drugs and cardiovascular safety : current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000 ; 26 : 62-72.
21. HAMILTON SP, NUNES E V, JANAL M et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000 ; 9 : 63-9.
22. HERRLIN K, SEGERDAHL M, GUSTAFSSON LL et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000 ; 356 : 2069-70.
23. KRANTZ MJ, KUTINSKY IB, ROBERTSON AD et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003 ; 23 : 802-5.
24. LAQUEILLE X, BAYLE FJ, SPADONE C et al. Treatment of depressive syndromes in detoxified drug addicts : use of methadone. Biomed Pharmacother 1996 ; 50 : 279-82.
25. LIU S J, WANG RI. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry 1984 ; 141 : 1287-8.
26. LOO H, LAQUEILLE X, REMI P et al. Treatment of heroin addicts by substitution with methadone. Importance, limits and experience in France. Bull Acad Natl Med 1993 ; 177 : 1315-25 ; discussion : 1326-31.
27. MAANY I, DHOPESH V, ARNDT IO et al. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry 1989 ; 146 : 1611-3.
28. MCCANCE-KATZ EF, RAINEY PM, JATLOW P et al. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune DeficSyndr Hum. Retrovirology 1998 ; 18 (5) : 435-43.
29. MCCANCE-KATZ EF, RAINEY PM, FRIEDLAND G et al. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003 ; 37 : 476-82.
30. NERI S, BRUNO CM, ABATE G et al. Controlled clinical trial assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002 ; 24 (10) : 1627-35.
31. NOVICK DM, KREEK MJ, ARNS PA et al. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res 1985 ; 9 : 349-54.
32. ODA Y, KHARASCH ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4) : potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001 ; 298 : 1021-32.
33. PERT CB, SNYDER SH. Opiate receptor : demonstration in nervous tissue. Science 1973 ; 179 : 1011-4.
34. PLUMMER JL, GOURLAY GK, CHERRY DA et al. Estimation of methadone clearance : application in the management of cancer pain. Pain 1988 ; 33 : 313-22.
35. RAINEY PM, FRIEDLAND G, MCCANCE-KATZ EF et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000 ; 24 : 241-8.
36. RECOMMENDATIONS ANAES 2004. Réduire les mauvaises utilisations des medicaments de substitution des opiacés. http:// www.anaes.fr.
37. REIMANN G, BARTHEL B, ROCKSTROH JK et al. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999 ; 37 : 562-6.
38. ROJAS-CORRALES MO, BERROCOSO E, GIBERT-RAHOLA J et al. Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci 2002 ; 72 (2) : 143-52.
39. ROSTAMI-HODJEGAN A, WOLFF K, HAY AW et al. Population pharmacokinetics of methadone in opiate users : characterization of time-dependent changes. Br J Clin Pharmacol 1999 ; 48 : 43-52.
40. SAXON AJ, WHITTAKER S, HAWKER CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism : two cases. J Clin Psychiatry 1989 ; 50 : 228-9.
41. SELWYN PA. and IEZZA A. Zidovudine overdose in an intravenous drug user. Aids 1990 ; 4 : 822-4.
42. THOMPSON SJ, KOSZDIN K, BERNARDS CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000 ; 92 : 1392-9.
43. TONG TG, POND SM, KREEK MJ et al. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981 ; 94 : 349-51.
44. VENKATAKRISHNAN K, GREENBLATT DJ, VON MOLTKE LL et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998 ; 38 : 112-21.
45. WOLFF K, HAY AW. Plasma methadone monitoring with methadone maintenance treatment. Drug Alcohol Depend 1994 ; 36 : 69-71 ; author reply : 73-65.
46. WOLFF K, ROSTAMI-HODJEGAN A, SHIRES S et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol 1997 ; 44 : 325-34.